Autoimmune Atherosclerosis: How Chronic Inflammation Accelerates Heart Disease in Women

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Atherosclerosis is increasingly understood as an inflammatory disease, not merely a problem of cholesterol accumulation. That reframing has a direct consequence for the millions of women living with autoimmune conditions, because the chronic systemic inflammation that defines those diseases accelerates the very process that drives heart attacks and strokes. Autoimmune disease is a cardiovascular risk factor, and because autoimmune disease skews strongly female, so does this risk.

The inflammatory mechanism

Inflammation participates at every stage of atherosclerosis, from endothelial activation to plaque formation to the instability that precedes rupture. 4 / Promising In autoimmune disease, persistent systemic inflammation amplifies this process, so the vascular damage accumulates faster and earlier than traditional risk factors alone would predict. The autoimmune condition adds an inflammatory burden on top of whatever conventional risk a woman already carries.

The magnitude in specific diseases

The clearest data come from lupus and rheumatoid arthritis. 4 / Promising In systemic lupus erythematosus, cardiovascular risk is substantially elevated and appears at younger ages than in the general population, with classic work documenting markedly higher myocardial infarction risk in younger women with lupus than would be expected for their age. Rheumatoid arthritis similarly carries elevated cardiovascular risk, and professional bodies recommend incorporating that excess risk into prevention. The common thread is accelerated, premature atherosclerosis driven substantially by inflammation.

Why it is a women’s issue, and why it gets missed

Most autoimmune diseases predominate in women, so autoimmune-driven cardiovascular risk is largely borne by women. 3 / Early It is also routinely under-addressed because the cardiovascular risk is overshadowed by management of the primary disease: the rheumatologist manages disease activity, the woman focuses on her symptoms, and the heart risk riding along with the inflammation is no one’s explicit responsibility. The fix is shared ownership of cardiovascular risk between specialties.

The biology of how inflammation builds plaques

To understand why autoimmune disease accelerates atherosclerosis, you need to understand what inflammation actually does inside an artery wall. The sequence begins at the endothelium, the single-cell lining of every blood vessel. Circulating inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6), activate endothelial cells and cause them to express adhesion molecules that recruit monocytes and T-lymphocytes from the bloodstream into the arterial wall. 4 / Promising

Once inside the vessel wall, monocytes differentiate into macrophages and begin engulfing oxidized low-density lipoprotein (LDL). The oxidation of LDL is itself promoted by the reactive oxygen species generated during inflammatory states. Macrophages loaded with oxidized LDL become foam cells, the histologic signature of early atherosclerotic lesions. Foam cells do not clear the LDL efficiently; they accumulate, die, and release their lipid contents into the arterial wall, forming the necrotic lipid core of a developing plaque.

T-lymphocytes, particularly CD4+ helper T-cells, amplify the process by releasing additional pro-inflammatory cytokines and by activating smooth muscle cells within the arterial wall. Activated smooth muscle cells migrate from the media into the intima and produce a fibrous cap over the lipid core. The stability of this cap is what determines whether a plaque is dangerous. Thin fibrous caps, undermined by ongoing matrix metalloproteinase activity driven by macrophages and T-cells, are prone to rupture. Plaque rupture exposes the lipid core to circulating blood and triggers the thrombus formation that causes most heart attacks and many strokes.

In autoimmune disease, the cytokines driving this cascade are chronically elevated. TNF-alpha and IL-6 in particular circulate at high levels in active lupus and rheumatoid arthritis, which means the endothelium is persistently activated, monocyte recruitment is continuous, and the environment within arterial walls is chronically pro-atherogenic. The result is not a faster version of ordinary atherosclerosis, but a biochemically distinct inflammatory process superimposed on the conventional lipid-driven one.

Lupus: the evidence that changed how cardiologists think

The landmark paper reorienting clinical thinking about lupus and cardiovascular risk is the 1997 cohort study by Manzi and colleagues, published in the American Journal of Epidemiology. Manzi et al. followed 498 women with systemic lupus erythematosus enrolled in the Pittsburgh Lupus Registry and documented that women with lupus aged 35 to 44 were 52 times more likely to have a myocardial infarction than age-matched women from the Framingham Offspring Study. That is not a modest elevation; it is a figure that demands a structural change in how lupus is managed. 4 / Promising

The magnitude in younger women was so striking that it prompted a reconceptualization: some investigators began framing lupus as a coronary artery disease equivalent, meaning the disease itself confers a risk level similar to having already had a prior cardiac event. That framing, while contested at the margins, has practical clinical logic because it implies that women with lupus deserve aggressive primary prevention rather than a watch-and-wait approach governed by age norms.

Subsequent work has refined the picture. The risk in lupus is not solely from inflammation; corticosteroid use, a cornerstone of lupus management, promotes hypertension, dyslipidemia, glucose intolerance, and weight gain, all of which compound the inflammatory vascular damage. Antiphospholipid antibodies, present in a substantial proportion of lupus patients, independently promote thrombosis at both small and large vessel levels. Renal disease in lupus adds hypertension and proteinuria to the cardiovascular risk profile. The cardiac risk in lupus is therefore a layered problem: the disease activity, the medications required to control it, and the complications it produces all converge on the same arterial endpoint.

Subclinical atherosclerosis data in lupus confirm the pathologic picture. Carotid intima-media thickness, a non-invasive ultrasound measure of early arterial wall thickening, is elevated in lupus patients compared to controls, and the elevation correlates with disease duration and inflammatory burden rather than simply with traditional risk factors. This is direct vascular evidence that the inflammatory mechanism is doing structural damage in ways that precede symptoms by years.

Rheumatoid arthritis: EULAR recommendations and the inflammation-cardiac risk link

Rheumatoid arthritis carries a cardiovascular risk elevation estimated at roughly 50 percent above the general population in large meta-analyses, with the excess concentrated in ischemic heart disease and heart failure rather than stroke. The European Alliance of Associations for Rheumatology (EULAR) has addressed this directly: EULAR recommendations published and subsequently updated through 2023 state that rheumatoid arthritis should be considered an independent cardiovascular risk factor, that formal cardiovascular risk assessment should be performed in all rheumatoid arthritis patients at least every five years, and that a multiplication factor of 1.5 should be applied to estimated ten-year risk scores to account for the disease-specific excess. 4 / Promising

The inflammatory markers that clinicians measure in rheumatoid arthritis, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Disease Activity Score in 28 joints (DAS28), track with cardiovascular event rates. Higher disease activity, as measured by these composite scores, predicts higher cardiac risk independent of traditional Framingham risk factors. This means that a rheumatoid arthritis patient with well-controlled disease has lower cardiovascular risk than one with persistently active disease, and the difference is not trivial.

The mechanism in rheumatoid arthritis overlaps substantially with lupus: circulating IL-6 and TNF-alpha at chronically elevated levels, endothelial dysfunction measurable early in the disease course, accelerated foam cell formation, and an increased proportion of thin-capped unstable plaques. One distinguishing feature of rheumatoid arthritis is the contribution of a specific immune cell subset, the anti-citrullinated protein antibody (ACPA)-producing B-cells, to systemic inflammation; ACPA positivity in rheumatoid arthritis is associated with higher cardiovascular risk than ACPA-negative disease, suggesting that the antibody-driven inflammatory component adds a distinct vascular burden.

Rheumatoid arthritis also illustrates a detection problem particular to autoimmune disease: patients with long-standing rheumatoid arthritis may present with heart attacks without preceding chest pain, because the same pain pathways that are altered by the disease’s neuropathic components may blunt anginal symptoms. The infarction presents as dyspnea or fatigue, which in a woman with rheumatoid arthritis can easily be attributed to the primary disease rather than triggering a cardiac evaluation.

Psoriasis, ankylosing spondylitis, and the broader inflammatory spectrum

The cardiovascular risk elevation is not confined to lupus and rheumatoid arthritis. Psoriasis, a systemic inflammatory condition far more common than either, carries documented excess cardiovascular risk with a magnitude that scales with disease severity. Severe psoriasis, defined by body surface area involvement or psoriatic arthritis, is associated with elevated rates of myocardial infarction and cardiovascular death in large registry studies. 3 / Early The inflammatory mechanisms parallel those in other autoimmune conditions, with elevated TNF-alpha, IL-17, and IL-23 playing the predominant roles.

Ankylosing spondylitis, which while not as female-predominant as lupus or rheumatoid arthritis still affects a substantial number of women, is associated with aortic root disease, cardiac conduction abnormalities, and elevated ischemic heart disease rates. The inflammatory burden in ankylosing spondylitis is particularly concentrated around the aortic root and the conduction system, which generates a distinctive cardiovascular phenotype that clinicians unfamiliar with the disease may not immediately connect to the inflammatory arthritis.

Inflammatory bowel disease, Sjogren’s syndrome, and systemic sclerosis all carry cardiovascular signal, with the mechanisms overlapping around chronic systemic inflammation, immune complex deposition, and endothelial activation. Women with systemic sclerosis face an additional problem: Raynaud’s phenomenon and microvascular disease that may produce cardiac symptoms through mechanisms distinct from classical atherosclerosis but equally consequential in terms of outcome.

The aggregate picture is that chronic inflammatory disease is a class-level cardiovascular risk factor, and many of the diseases in that class are predominantly or disproportionately carried by women.

Biomarkers: what CRP, hsCRP, and ESR add to cardiovascular risk assessment

Standard cardiovascular risk calculators, including the ACC/AHA Pooled Cohort Equations used in the United States, do not include inflammatory biomarkers. They use age, sex, race, total cholesterol, HDL, systolic blood pressure, diabetes status, and smoking. For a woman with rheumatoid arthritis or lupus, this produces an underestimate of true risk, because the inflammatory burden the disease adds is invisible to the calculator. 4 / Promising

High-sensitivity CRP (hsCRP) is the most studied inflammatory biomarker in general cardiovascular risk assessment. The JUPITER trial, led by Ridker and colleagues and published in the New England Journal of Medicine in 2008, randomized over 17,000 individuals with elevated hsCRP but normal LDL to rosuvastatin versus placebo and found a significant reduction in cardiovascular events in the treated group. The implication was that elevated hsCRP marks residual cardiovascular risk not captured by lipid measurements alone.

In autoimmune disease populations, hsCRP and ESR function both as disease activity markers and as cardiovascular risk signals, and the two roles are entangled: when disease is active, both rise; when disease is controlled, both fall. This means a woman with well-controlled rheumatoid arthritis and a low CRP may actually have a lower cardiovascular risk than a woman with the same cholesterol profile and uncontrolled disease activity with a high CRP. The biomarker reflects the disease state that drives the risk.

ESR captures a broader set of acute-phase reactants than CRP and is less specific, but in the context of tracking cardiovascular risk alongside disease activity, serial ESR measurements over years provide a rough proxy for cumulative inflammatory exposure. Neither hsCRP nor ESR alone is sufficient to replace clinical judgment in autoimmune disease patients, but ignoring them when calculating cardiovascular risk leaves out information that changes management decisions.

Interleukin-6 measurement is gaining clinical traction as a direct inflammatory cytokine rather than a downstream marker. IL-6 drives both the acute-phase response that elevates CRP and the direct vascular effects that promote atherosclerosis. In rheumatoid arthritis patients receiving tocilizumab, an IL-6 receptor antagonist, LDL levels rise as a pharmacologic consequence of blocking IL-6’s effect on lipid metabolism, which has complicated cardiovascular risk interpretation in that drug class. The LDL rise accompanies a reduction in systemic inflammation, and the net cardiovascular effect appears to be neutral to slightly favorable in observational data, though the mechanistic complexity illustrates why biomarker interpretation in autoimmune disease requires disease-specific knowledge.

Disease activity control as cardiovascular prevention

The most direct evidence that inflammation drives the cardiovascular excess in autoimmune disease comes from studies showing that controlling disease activity reduces cardiac events. In rheumatoid arthritis, meta-analyses of biologic therapy, particularly TNF inhibitors, show significant reductions in cardiovascular event rates compared to patients with uncontrolled disease or conventional synthetic DMARD treatment alone. 4 / Promising This is not a small signal: the reduction in myocardial infarction risk associated with effective TNF inhibition in rheumatoid arthritis is large enough to argue that adequate disease control is itself a cardiovascular intervention.

The picture in lupus is more complicated because the primary immunosuppressive agents used in lupus, corticosteroids and mycophenolate, carry their own cardiovascular side effects. Hydroxychloroquine is the notable exception: it is the one lupus medication consistently associated with improved cardiovascular outcomes, through anti-inflammatory, lipid-lowering, and anti-thrombotic mechanisms. Continued use of hydroxychloroquine in lupus patients has been associated in multiple observational studies with lower rates of cardiovascular events, and its discontinuation is associated with disease flares that themselves carry cardiovascular cost. This makes hydroxychloroquine adherence part of the cardiovascular management of lupus, not merely part of the rheumatologic management.

For psoriasis, IL-17 inhibitors and IL-23 inhibitors have shown signal for cardiovascular risk reduction in observational data, and the question of whether biologic control of psoriasis constitutes cardiovascular prevention is an active research question rather than a settled one. The available data are promising but not yet sufficient for formal guideline endorsement.

The practical clinical implication is that when a woman with autoimmune disease and her rheumatologist are making decisions about escalating, de-escalating, or changing therapy, cardiovascular risk is legitimately part of that calculus. Sustained disease activity is not a neutral background condition for the heart.

What women with autoimmune disease should ask their care team

The gap between current evidence and current practice is real. Women with autoimmune disease are frequently not receiving formal cardiovascular risk assessment, not having their inflammatory markers incorporated into prevention planning, and not being counseled that disease control is partly a cardiac strategy. Closing that gap requires women to bring these questions directly into their clinical encounters.

The questions for the rheumatologist: Has my cardiovascular risk ever been formally calculated using a tool that accounts for my autoimmune disease? Is my current level of disease control consistent with minimizing the inflammatory burden on my arteries? Does my treatment plan include hydroxychloroquine or a biologic agent that has shown cardiovascular benefit? Have you shared my disease activity history with my cardiologist or primary care physician?

The questions for the cardiologist or primary care physician: Have you adjusted my cardiovascular risk estimate upward to account for my autoimmune disease? Have you reviewed my inflammatory markers, including CRP or ESR, as part of my cardiac risk profile? Am I on statin therapy, and if not, have we discussed whether my inflammatory baseline changes that calculation? Have you looked at my carotid intima-media thickness or ordered coronary artery calcium scoring to establish my actual vascular age rather than relying only on my chronological age?

These are not confrontational questions; they are requests for care that is already recommended in published guidelines and professional society statements. The problem is not that the guidelines are missing but that implementation across specialties is inconsistent. A woman asking her rheumatologist about cardiovascular risk and her cardiologist about inflammatory markers is connecting two conversations that should already be connected but often are not.

What this means

Autoimmune disease accelerates atherosclerosis through chronic inflammation, raising cardiovascular risk and bringing it forward in time, and it falls disproportionately on women. The corrective is to treat autoimmune disease as a cardiovascular risk factor, start prevention early rather than by standard age thresholds, manage traditional risk factors aggressively, and recognize control of disease activity as part of protecting the heart. Inflammation is the link, and naming it changes the timeline of care.